Altered MicroRNA Expression in the Ischemic^|^ndash;Reperfusion Spinal Cord With Atorvastatin Therapy

Hu, Jiarui; Lv, Guohua; Yin, Bin

doi:10.1254/jphs.12235sc

Cited by 37 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8. Specifically, in differentiating SCI from SHAM groups, miR-133a-5p 25 (AUC = 0.95, p < 0.0001), miR-378 26 (AUC = 0.91, p < 0.0001), miR-378b-3p 26 (AUC = 0.90, p < 0.0001), miR-365-3p 27 (AUC = 0.89, p < 0.0001), miR-133b 28, 29 (AUC = 0.89, p < 0.0001), miR-10b 30 (AUC = 0.88, p < 0.0001), miR-885-5p (AUC = 0.88, p < 0.0001), miR-130a (AUC = 0.88, p < 0.0001), miR-100 26, 31 (AUC = 0.88, p < 0.0001), and miR-208b 32 (AUC = 0.87, p < 0.0001) showed the highest AUC values, some of which have been shown to have alterations after CNS injuries. In distinguishing severe from mild SCI, miR-423-3p (AUC = 1.00, p = 0.0008), miR-425-5p (AUC = 1, p = 0.0008), miR-486 33 (AUC = 1, p = 0.0008), miR-100 26, 31 (AUC = 0.97, p = 0.0016), miR-10b 30 (AUC = 0.94, p = 0.0033), miR-378 26 (AUC = 0.94, p = 0.0033), miR-204 34 (AUC = 0.92, p = 0.0046), miR-22-5p (AUC = 0.92, p = 0.0046), miR-378b-3p 26 (AUC = 0.92, p = 0.0046), and miR-125b 35 (AUC = 0.91, p = 0.0063) showed the highest AUC values some of which have been shown to have alterations after CNS injuries.…”

Section: Resultsmentioning

confidence: 99%

Serum MicroRNAs Reflect Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury

Tigchelaar

Streijger

Sinha

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Therapeutic development for spinal cord injury is hindered by the difficulty in conducting clinical trials, which to date have relied solely on functional outcome measures for patient enrollment, stratification, and evaluation. Biological biomarkers that accurately classify injury severity and predict neurologic outcome would represent a paradigm shift in the way spinal cord injury clinical trials could be conducted. MicroRNAs have emerged as attractive biomarker candidates due to their stability in biological fluids, their phylogenetic similarities, and their tissue specificity. Here we characterized a porcine model of spinal cord injury using a combined behavioural, histological, and molecular approach. We performed next-generation sequencing on microRNAs in serum samples collected before injury and then at 1, 3, and 5 days post injury. We identified 58, 21, 9, and 7 altered miRNA after severe, moderate, and mild spinal cord injury, and SHAM surgery, respectively. These data were combined with behavioural and histological analysis. Overall miRNA expression at 1 and 3 days post injury strongly correlates with outcome measures at 12 weeks post injury. The data presented here indicate that serum miRNAs are promising candidates as biomarkers for the evaluation of injury severity for spinal cord injury or other forms of traumatic, acute, neurologic injury.

show abstract

Section: Resultsmentioning

confidence: 99%

Serum MicroRNAs Reflect Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury

Tigchelaar

Streijger

Sinha

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Additionally, miR-146 regulates the toll-like receptor pathways and nuclear factor-κB-dependent inflammatory responses by targeting the 3'-UTR of TRAF-6 and IRAK-1. miR-199a-3p targets IκB kinase β, MET and extracellular-signal-regulated kinase (ERK)-2, thereby controlling inflammation and ERK-MAPK signaling, which has been proven to participate in injury following ischemia-reperfusion injury (IRI) (27).…”

Section: Cerebral Ischemiamentioning

confidence: 99%

Neuroprotection of microRNA in neurological disorders (Review)

Wang

Cheng

et al. 2014

Biomedical Reports

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are small, endogenous, non-coding RNA molecules that function as post-transcriptional regulators of gene expression by imperfect base-pairing with the 3'-untranslated regions of their target mRNAs. Altered expression of numerous miRNAs has been shown to be extensively involved in the pathogenesis of various diseases and cancers. Additionally, the specific expression of miRNAs in the nervous system has indicated that miRNAs are critical for the occurrence and development of neurological diseases. Increasing evidence has shown that specific miRNAs target the expression of particular proteins that are significant in the disease pathogenesis. Therefore, miRNA-mediated regulation may be important in the occurrence and development of neurological diseases and may function as a novel biomarker and tool for clinical therapy. In the present study, the significance of miRNAs is reviewed in a number of neurological disorders and the possibility of their use in therapeutic interventions is evaluated.

show abstract

“…In a rat model of spinal cord IRI [29], some anti-inflammatory mRNAs such as annexin A7 mRNA were potential targets of miR-323. Conversely, some inflammatory mediator mRNAs such as integrin, TNF- α , IL-1 β , TNF receptor-associated factor 6, interleukin-1 receptor-associated kinase 1, and CD80 mRNAs were potential targets of miR-210, miR-146a, and miR-199a-3p, which were downregulated after spinal cord IRI [29]. …”

Section: Cytokines In Spinal Cord Irimentioning

confidence: 99%

Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury

Zhu

Fujino

et al. 2013

Mediators of Inflammation

View full text Add to dashboard Cite

During aortic surgery, interruption of spinal cord blood flow might cause spinal cord ischemia-reperfusion injury (IRI). The incidence of spinal cord IRI after aortic surgery is up to 28%, and patients with spinal cord IRI might suffer from postoperative paraplegia or paraparesis. Spinal cord IRI includes two phases. The immediate spinal cord injury is related to acute ischemia. And the delayed spinal cord injury involves both ischemic cellular death and reperfusion injury. Inflammation is a subsequent event of spinal cord ischemia and possibly a major contributor to spinal cord IRI. However, the development of inflammatory mediators is incompletely demonstrated. And treatments available for inflammation in spinal cord IRI are insufficient. Improved understanding about spinal cord IRI and the development of inflammatory cells and cytokines in this process will provide novel therapeutic strategies for spinal cord IRI. Inflammatory cytokines (e.g., TNF-α and IL-1) may play an important role in spinal cord IRI. For treatment of several intractable autoimmune diseases (e.g., rheumatoid arthritis), where inflammatory cytokines are involved in disease progression, anti-inflammatory cytokine antagonist is now available. Hence, there is great potential of anti-inflammatory cytokine antagonist for therapeutic use of spinal cord IRI. We here review the mediators and several possibilities of treatment in spinal cord IRI.

show abstract

Altered MicroRNA Expression in the Ischemic^|^ndash;Reperfusion Spinal Cord With Atorvastatin Therapy

Cited by 37 publications

References 15 publications

Serum MicroRNAs Reflect Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury

Serum MicroRNAs Reflect Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury

Neuroprotection of microRNA in neurological disorders (Review)

Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury

Contact Info

Product

Resources

About